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spondyloarthritis, especially psoriatic arthritis, to 
target: 2017 update of recommendations by an 
international task force
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Oliver FitzGerald,6 Dafna D Gladman,7 Arthur Kavanaugh,8 Robert Landewé,9 
Philip Mease,10 Joachim Sieper,11 Tanja Stamm,12 Maarten de Wit,13 Daniel Aletaha,1 
Xenofon Baraliakos,4 Neil Betteridge,14 Filip van den Bosch,15 Laura C Coates,16 
Paul Emery,17 Lianne S Gensler,18 Laure Gossec,19 Philip Helliwell,20 Merryn Jongkees,21 
Tore K Kvien,22 Robert D Inman,23 Iain B McInnes,24 Mara Maccarone,25 
Pedro M Machado,26 Anna Molto,5 Alexis Ogdie,27 Denis Poddubnyy,11,28 
Christopher Ritchlin,29 Martin Rudwaleit,11,30 Adrian Tanew,31 Bing Thio,32 
Douglas Veale,33 Kurt de Vlam,34 Désirée van der Heijde35
AbstRAct
Therapeutic targets have been defined for axial and 
peripheral spondyloarthritis (SpA) in 2012, but the evidence 
for these recommendations was only of indirect nature. 
These recommendations were re-evaluated in light of new 
insights. Based on the results of a systematic literature 
review and expert opinion, a task force of rheumatologists, 
dermatologists, patients and a health professional 
developed an update of the 2012 recommendations. 
These underwent intensive discussions, on site voting 
and subsequent anonymous electronic voting on levels 
of agreement with each item. A set of 5 overarching 
principles and 11 recommendations were developed 
and voted on. Some items were present in the previous 
recommendations, while others were significantly changed 
or newly formulated. The 2017 task force arrived at a 
single set of recommendations for axial and peripheral 
SpA, including psoriatic arthritis (PsA). The most exhaustive 
discussions related to whether PsA should be assessed 
using unidimensional composite scores for its different 
domains or multidimensional scores that comprise multiple 
domains. This question was not resolved and constitutes an 
important research agenda. There was broad agreement, 
now better supported by data than in 2012, that remission/
inactive disease and, alternatively, low/minimal disease 
activity are the principal targets for the treatment of PsA. As 
instruments to assess the patients on the path to the target, 
the Ankylosing Spondylitis Disease Activity Score (ASDAS) 
for axial SpA and the Disease Activity index for PSoriatic 
Arthritis (DAPSA) and Minimal Disease Activity (MDA) for 
PsA were recommended, although not supported by all. 
Shared decision-making between the clinician and the 
patient was seen as pivotal to the process. The task force 
defined the treatment target for SpA as remission or low 
disease activity and developed a large research agenda to 
further advance the field.
IntRoductIon
Recommendations on general treatment targets in 
spondyloarthritis (SpA) and the strategy to treat 
SpA to these targets were developed in 2012 by an 
international task force.1 These recommendations 
are deliberately generic and intended to inform 
the optimal treatment approach rather than advise 
around a specific drug entity, since it was deemed 
important to develop and describe a conceptual 
framework independent of particular drug avail-
ability or preference. Other groups have focused on 
drug therapies in management recommendations 
for axial SpA and psoriatic arthritis (PsA)2–4; two of 
the three management recommendations adopted 
the treat-to-target (T2T) concept.2 4 This concept, 
originally developed for chronic diseases such as 
diabetes,5 has already been successfully imple-
mented for rheumatoid arthritis (RA).6 Systematic 
literature reviews (SLRs) underpinning the T2T 
recommendations for RA revealed data from several 
trials with efficacy of a target-driven therapeutic 
approach as superior to usual clinical care in RA for 
clinical, functional and structural outcomes.7 8 The 
2012 task force applied this concept to SpA, despite 
the fact that the SLR on the original T2T recom-
mendations for SpA revealed only indirect evidence 
favouring this approach, given the absence of data 
from strategic clinical trials.9
All recommendations developed in 2012 for SpA 
treatment to target were based on evidence levels of 
the lowest category1 (category 5),10 which derives 
solely from expert opinion, even if they were based 
on several lines of indirect evidence. Therefore, 
an ambitious research agenda was then proposed 
to focus on improving the definition of treatment 
targets and validating respective instruments and 
emphasised the importance of data collection from 
strategic clinical trials. The participants under-
stood such limitations and in the manuscript it was 
stated at the time that ‘given the small evidence 
base, the research agenda is of utmost importance’, 
anticipating a revision of the document ‘in about 
4 years or 5 years…, when significant evidence 
accumulates regarding the individual points of the 
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recommendations’ that ‘either allow confirmation or modifica-
tions’ of the conclusions.1
Subsequently, in line with those expectations, a number of 
publications in the field have addressed several points raised in 
the research agenda. Therefore, our objective was to re-evaluate 
and update the recommendations.
Methods
At the beginning of this endeavour, a steering committee (SC) 
comprising rheumatologists from Europe and North America 
experienced in SpA clinical research, a patient and a health 
professional (in total 13 members) was convened in August 2016 
in Vienna, Austria, by a rheumatologist (JSS) and a methodolo-
gist (DvdH) to discuss the potential need for a recommendation 
update based on the information available from the literature 
published in recent years. Research questions for an update 
of the systematic literature review (SLR)9 were formulated by 
the SC members; the process adhered to the updated Euro-
pean League Against Rheumatism (EULAR) standard operating 
procedures (SOPs) for developing recommendations.11 The SLR, 
which was performed by MS and covered the period from the 
last SLR (2011) to the end of 2016 is summarised in the online 
supplementary material A. It was presented at a 2-day meeting 
in March 2017 in Düsseldorf, Germany. The detailed SLR was 
reported to the SC. The SC then carefully reviewed every item 
of the overarching principles and recommendations developed 
in 2012 and proposed an amended set of recommendations for 
discussion by the whole task force.
The next day, the task force comprising 36 members was 
convened (one additional expert, TKK, was involved in the 
planning of the activity and in the level of agreement voting 
and manuscript development process). Among these members 
were four patient representatives (NB, MJ, MM, MdW), 1 (non-
MD) health professional (TS), 2 dermatologists (AT, BT) and 28 
rheumatologists, 6 of whom came from North America with the 
remainder coming from Europe. All experts had a significant 
publication record in the field of SpA. Indeed, several of the 
experts are also committee members of the Group for Research 
and Assessment of Psoriatic Arthritis (GRAPPA; www. grappanet-
work. org/ committee- list) and coauthors of the 2015 GRAPPA 
PsA treatment recommendations; another group of experts 
is involved in Assessment of SpondyloArthritis international 
Society (ASAS) activities (http:// asas- group. org/ committee. php) 
and participated in the development of the ASAS-EULAR axial 
SpA management recommendations4 and a third group has 
been involved in the generation of the EULAR PsA manage-
ment recommendations,2 with some small overlap among these 
involvements.
In line with the SOPs, no representative of the company 
providing the unrestricted grant was present to avoid any poten-
tial influence on the discussion or development of the recom-
mendations; this position has been and still is a general principle 
throughout all T2T activities.
At the beginning, the convenor summarised the 2012 recom-
mendations together with the 2012 discussions. In particular, 
the 2012 task force had originally contemplated developing 
three sets of recommendations, namely one for axial SpA, one 
for peripheral SpA excluding PsA and one for PsA. During the 
2012 process, it became apparent that the three proposed sets 
had significant overlap such that the final recommendations 
comprised a common trunk of five overarching principles and 
nine recommendations, as well as two recommendations each 
for axial SpA, PsA and peripheral SpA.
Given the recent proliferation of instruments (categorical and 
continuous) for evaluating the multiple domains of PsA,12 one of 
the SC members (OF) presented a summary of these measures to 
the task force. The methodologist (DvdH) addressed the scien-
tific and methodological background of selecting components of 
composite indices for chronic rheumatic diseases.
An abbreviated version of the SLR was then presented to the 
task force (MS) with residual information available on request. 
Of note, very few data exist for peripheral SpA and, therefore, 
in line with the results of the SLR, the current activity focused 
on axial SpA and PsA.
For the discussion and decision-making process of the recom-
mendations, each item of the 2012 version was shown together 
with the SC proposal for the new version. Each of the items 
was subjected to a thorough discussion in light of the evidence 
presented and to a rigorous voting process. The methodologist 
explained that, as in the previous and similar endeavours,1 4 13 the 
initial ballot required at least 75% of votes to accept a proposal 
for a recommendation. If this result was not achieved, textual 
amendments were discussed and in the next round 67% of the 
votes were needed. If that amendment was not sufficient, the 
process continued and then a member vote of >50% was needed 
for approval and acceptance.
The level of evidence (LoE) and strength or recommenda-
tion (SoR) was based on the Oxford Evidence-Based Medicine 
categorisation.10
After the meeting, the newly formulated recommendations 
were compiled in a single table together with the LoE, SoR and 
voting results at the meeting. All task force members assigned 
electronically (by email) and anonymously level of agreement 
(LoA) with each item on a scale of 0 (no agreement at all) to 10 
(full agreement).
Results
General aspects
Implementation, feasibility and validity
A central question, mentioned by the convenor in his introduc-
tory remarks, concerned the implementation of the previous 
recommendations. Implementation may be supported by the 
fact that both EULAR PsA and ASAS-EULAR axial SpA manage-
ment recommendations have adopted the T2T approach. The 
T2T recommendations for RA were also strongly integrated into 
the respective American College of Rheumatology (ACR) and 
EULAR management guidance documents.13 14 Nevertheless, 
implementation is often impeded in clinical practice.15 Learning 
collaboratives, that is, group-based multisite educational collab-
oratives, can be successful in this respect.16
In some practice settings, effective implementation is attained 
when rheumatologists have to enter detailed data into registries.17 
However, even if rheumatologists agree with certain principles, 
the practical application of these principles may be limited.18 A 
recent survey revealed that ‘a busy clinical practice, accompa-
nied by a shortage of supporting staff, was identified as the main 
barrier to full compliance with the T2T recommendations from 
the physician standpoint’.19 Indeed, ‘limitations arise as a result 
of … lack of time for the individual patient with RA’,20 21 despite 
the fact that the T2T-RA recommendations only call for using 
a composite measure for RA disease activity that includes joint 
counts.1 Since T2T recommendations are developed primarily 
for clinical practice, feasibility should be a major character-
istic, among others, in line with the Appraisal of Guidelines for 
Research and Evaluation II guidelines, which call for applicability 
and consideration of resource implications when developing 
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recommendations.22 In other words, a measure is feasible when 
it can ‘be applied easily, given constraints of time, money or 
interpretability’ despite the complexity of its development.23 
In addition, the composite ‘measure must discriminate between 
situations of interest’, be truthful, that is, have face, construct, 
content and criterion validity and demonstrate reliability.23 
Notably, health professionals in rheumatology may support the 
implementation and practice of T2T recommendations.
Instruments for PsA
In the presentation on the measures used for PsA assessment, 
several different instruments, their components and calculations 
were addressed and are shown in table 1. They comprise the 
Composite Psoriatic Disease Activity Index (CPDAI),24 Disease 
Activity index for PSoriatic Arthritis (DAPSA),25 GRAppa 
Composite Exercise (GRACE) index,26 Minimal Disease 
Activity (MDA)27 and Psoriatic Arthritis Disease Activity Score 
(PASDAS).12 Most of these instruments allow calculation of 
continuous scores, while one (MDA) is dichotomous or cate-
gorical. The continuous scales can also be applied to define 
disease activity categories or states. One measure focuses only 
on joint activity (DAPSA), the others also include measures of 
other (non-articular) musculoskeletal domains (such as enthesitis 
and axial disease), skin manifestations, physical functioning or 
quality of life (table 1).
Selection of domains for composite measures of disease activity
The presentation on the selection of components for composite 
disease activity measures focused on axial SpA. Issues of 
methodological rigour, instrument properties pertaining to 
composite measures and the preference of a unidimensional 
approach to disease activity assessment were discussed.28 Addi-
tionally, the concern of combining domains into a composite 
that may not track together, particularly regarding response to 
therapy, was addressed, since the risk increases of missing true 
improvement in individual domains, or missing non-response 
or deterioration in other domains. Moreover, in this situa-
tion a good performance of one dimension can ‘compensate’ 
for a bad result in another dimension despite being different 
disease manifestations. This may not be the case when the 
disease domains are assessed separately with respective vali-
dated instruments. For example, uveitis occurs frequently in 
patients with axial SpA (>20%) and concomitant psoriasis or 
inflammatory bowel disease (IBD) are not rare.29 30 However, 
uveitis activity31 since relating to a different domain should 
not be part of an index for axial SpA.
It was also noted that composites should not combine 
a measure of inflammation with a measure of structural 
changes or physical functional, since damage and function 
are different constructs than activity. While they are partly a 
consequence of the inflammatory process, they do not reflect 
this process directly (figure 1). Furthermore, when outcome 
measures are combined with activity measures, the ability to 
detect improvement might preclude a subgroup of patients 
with long-standing disease from achieving remission despite 
experiencing clear-cut absence of inflammation.32–35 More-
over, when the data from these instruments are correlated 
with physical function as an outcome, circular reasoning may 
ensue. Therefore, ASAS improvement and partial remission 
criteria, which include function (table 2),36 are less discrimi-
native and appropriate than the respective Ankylosing Spon-
dylitis Disease Activity Score (ASDAS) categories.37 t
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In general, composite measures have the advantage of encom-
passing various aspects linked to a construct, such as inflamma-
tion. For example, in RA and also PsA joint swelling and acute 
phase reactant (APR) levels are more strongly associated with 
progression of joint damage, than joint tenderness,38–41 patient 
global and pain assessments, while the latter are more strongly 
associated with disability than damage; a composite measure that 
combines these individual variables reflecting current disease 
activity will, therefore, relate to the totality of future adverse 
disease outcomes.42–44 Of note, the term ‘outcome’ is frequently 
used interchangeably with the term ‘end point’ (of an interven-
tion, ie, outcome of a treatment or a study), while here it will 
be used primarily to reflect the sequel of diseases like axial SpA 
and PsA.
A number of task force members believe that in PsA, as a 
multidimensional disease, one should be aiming to measure 
psoriatic disease as a construct and, therefore, the instrument 
needed to combine individual domains into a single ‘snapshot’ 
of the disease; moderate disease activity in several domains 
may altogether contribute to a single score representing high 
disease activity and response criteria and cut-offs will reflect 
the disease as a whole. Others are of the opinion that espe-
cially in a multidimensional disease unidimensional scoring 
of the individual components is pivotal to understand the 
heterogeneity in an individual patient and especially thera-
peutic effects on the individual domains. By this reasoning all 
disease manifestations should be assessed, but separately and 
not within one index (a unidimensional approach). Indeed, 
just like in RA or axial SpA, where management recommen-
dations relate to the respective levels of disease activity,4 13 14 
the most recent management recommendations for PsA relate 
to the level of activity of the individual domains and not a 
total score of psoriatic disease.2 3 It is also noteworthy that the 
recent approvals by regulatory authorities of all novel thera-
pies for PsA were based on clinical trials using unidimensional 
primary end points, even though they were derived from 
RA and were thus not specific for PsA joint involvement nor 
other manifestations of the disease. While the ACR response 
criteria include a measure of physical function, it is one of five 
measures (of which three need to be fulfilled) that can only be 
used if joint counts improve by a minimum of 20%, 50% or 
70%.45 In post hoc subanalyses, however, several of the newer 
composite scores such as PASDAS were evaluated26 and newer 
trials are including composite multidimensional measures 
related to all domains and/or the unidimensional DAPSA as 
key outcomes.
During the meeting and in the process of developing the 
manuscript, no clear agreement emerged between these two 
schools of thought. Most of the participants who advocated 
multidimensional scores were members of GRAPPA commit-
tees, while most of those advocating unidimensional scoring 
approaches were not. Thus, it appears that this is still an area 
of research that needs to be growing and methods of defining 
validity are developing.46 47 To this end, several ongoing 
studies are aiming to further define the optimal outcome 
measures for PsA.
the consensus
overarching principles
Providing a framework to embed the individual recommenda-
tions was important. Such a framework has been studied rarely 
in a methodological fashion. Therefore, the previous document 
already included ‘principles’ that govern and underscore the 
realisation of the recommendations.1 The current task force 
adhered to this approach and agreed on five overarching princi-
ples, in line with the 2012 recommendations.
A. The treatment target must be based on a shared decision 
between patient and rheumatologist. This first principle 
remained unchanged. It is fundamental to good clinical 
practice and constitutes a quality indicator of patient care 
in other diseases.48 There was discussion whether the term 
‘target’ should be changed to ‘targets’, because SpA exhibits 
clinical heterogeneity and patients and rheumatologists 
wish to achieve the treatment target across disease domains, 
whether musculoskeletal or extramusculoskeletal. A 
counterargument addressed the point that the singular 
‘target’, which focuses on a state to be attained, pertains 
to the outcome of all domains. Furthermore, ‘treatment 
targets’ is a term that is rarely, if ever used and might require 
Figure 1 Relationships between inflammation, damage and disability. Inflammation, by virtue of pain and stiffness, elicits disability which is 
reversible on reversal of disease activity. Inflammation also induces damage which is usually irreversible. Damage also induces disability; due to 
its irreversible nature, damage-induced disability is irreversible, meaning that with increasing damage the floor of physical functioning that can be 
reached on reversal of disease activity rises. 
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clarification for patients and rheumatologists. The patients 
felt strongly about the need for physicians to adhere to 
evidence-based therapies and to educate patients on the 
importance of such therapies versus unproven approaches. 
While there was broad agreement here, this aspect was felt 
to be more appropriate for the individual recommendations 
(to be discussed subsequently) and to drug management 
guidance documents. In a first ballot, the 75% majority 
needed was not obtained; the principle as worded and the 
original singular version of ‘target’ then received 69.4% 
approval in the second ballot.
B. Treatment to target by measuring disease activity, and 
adjusting therapy accordingly, improves outcomes. Since the 
previous version of these recommendations, evidence for the 
benefit of a T2T strategy compared with routine care has 
been obtained for PsA in the TICOPA trial.49 Therefore, it 
was proposed to replace the previous wording ‘contributes to 
short-term and/or long-term outcomes’ simply by ‘improves 
outcomes’. Although no T2T study has been performed in 
axial SpA, it was deemed that such an approach could also 
improve outcomes in axial SpA, given the correlation of 
damage progression with disease activity.50 51 T2T studies 
are currently ongoing in axial SpA (eg, TICOSPA, NCT 
03043846, and STRIKE, NCT 02897115). In the course of 
the deliberations, it was mentioned that the efficacy benefit 
of a T2T approach in PsA was somewhat counterbalanced 
by more adverse events in the TICOPA trial,49 however, this 
may be related to therapy choice (rapid csDMARD escalation 
and combinations) and partially due to reporting bias (T2T 
patients were reviewed every 4 weeks, controls every 12 
weeks) rather than the T2T strategy itself. Nevertheless, 
as will be detailed in the individual recommendations 
table 2 Clinical assessment of axial spondyloarthritis
bAsdAI62 Questions calculation
1. How would you describe the overall level of fatigue/tiredness you have 
experienced?
Assess each question on a numerical rating scale (NRS) of 0 (none) 
to 10 (very severe), alternatively, a VAS can be used for questions 
1–5 (NRS preferred by ASAS)
Calculation of BASDAI:
 ► Compute the mean of questions 5 and 6
 ► Calculate the sum of the values of question 1–4 and add the 
result to the mean of questions 5 and 6
 ► Divide the result by 5
2. How would you describe the overall level of ankylosing spondylitis neck, 
back or hip pain you have had?
3. How would you describe the overall level of pain/swelling in joints other 
than neck, back or hips you had?
4. How would you describe the overall level of discomfort you have had from 
any areas tender to touch or pressure?
5. How would you describe the overall level of morning stiffness you have had 
from the time you wake up?
6. How long does your morning stiffness last from the time you wake up?
AsdAs84 89 Parameters calculations
1. Total back pain (BASDAI question 2) ASDAS-CRP: 0.121 x total back pain+0.110 x patient 
global+0.073 x peripheral pain/swelling+0.058 x duration 
of morning stiffness+0.579xln(CRP+1); ASDAS-ESR: 
0.113xpatient global+0.293x√ESR+0.086 x peripheral pain/
swelling+0.069 x duration of morning stiffness+0.079xtotal back 
pain
Assess each question on an NRS of 0 (none) to 10 (very severe)
2. Patient global assessment
3. Peripheral pain/swelling (BASDAI question 3)
4. Duration of morning stiffness (BASDAI question 6)
5. C reactive protein (CRP) in mg/L (or erythrocyte sedimentation rate (ESR))
(the lowest value for CRP can be 2 mg/L)
Improvement criteria
ASAS 2090 Improvement ≥20% and absolute improvement of ≥1 unit (on a scale of 
0–10; or 10 units on a scale of 0–100) in at least three of the four following 
domains:
Patient global assessment
Pain
Function (BASFI)63
Inflammation (mean of morning stiffness-related BASDAI VAS scores for 
questions 5 and 6)
  No worsening of ≥20% and ≥1 unit in the remaining domain
ASAS 4091 Improvement ≥40% and absolute improvement of ≥2 unit (on a scale of 
0–10; or 10 units on a scale of 0–100) in at least three of the four following 
domains:
Patient global assessment
Pain
Function (BASFI)63
Inflammation (mean of morning stiffness-related BASDAI VAS scores for 
questions 5 and 6)
No worsening at all in the fourth domain
Remission criteria
  ASAS partial remission90 A value not above two units on a 0–10 scale in each of the four domains: 
patient global, pain, function, inflammation (mean of morning stiffness-
related BASDAI VAS scores for questions 5 and 6)*
  ASDAS inactive disease84 ASDAS <1.3
ASAS, Assessments of SpondyloArthritis international Society90; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity 
Index62; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, Visual Analogue Scale.
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and mentioned in principle C, safety aspects have to be 
considered when using a T2T approach. Thus, it was 
suggested to mention that for axial SpA this principle should 
currently be read as ‘T2T is based on the assumption that it 
improves outcomes’. Despite these caveats, the new wording 
was accepted by a majority of task force members (83.3%) 
in the first ballot.
C. SpA and PsA are multifaceted systemic diseases; the 
management of musculoskeletal and extra-articular 
manifestations should be coordinated, as needed, between the 
rheumatologist and other specialists (such as dermatologists, 
gastroenterologists, ophthalmologists). The original version: 
‘SpA and PsA are often complex systemic diseases’ was 
changed in two aspects: first, ‘complex’ was deemed by 
some to suggest that these diseases are too complicated to 
be understood, while it was used in 2012 to address the 
disease heterogeneity. Various additional aspects, especially 
concerning the term ‘extra-articular manifestations’, 
were discussed and are provided in online supplementary 
material B. The term ‘extra-articular’ will refer to non-
musculoskeletal abnormalities, such as the skin or the eye; 
indeed, current management recommendations separate 
these domains regarding specific treatment approaches.2 3 
However, the management recommendations also separate 
arthritis from other musculoskeletal manifestations; 
therefore, we will refer to axial disease, dactylitis and 
enthesitis as ‘non-articular musculoskeletal manifestations’ 
for the sake of semantic consistency and differentiation from 
‘extra-articular’ manifestations. Furthermore, replacing 
‘specialists’ by ‘specialties’ was discussed, but did not find 
popularity. Finally, it was suggested to expand ‘extra-articular’ 
to ‘extra-articular and other manifestations’ to also account 
for cardiovascular risk and other comorbidities; however, this 
also did not find major agreement, since these comorbidities, 
while serious and to be taken into account when following 
patients with SpA, constitute primarily consequences of 
chronic inflammation in general, rather than extra-articular 
manifestations of the underlying SpA, which are the focus of 
the current endeavour. Changing ‘complex’ to ‘multifaceted’ 
achieved 100% approval, maintaining ‘specialists’ rather 
than changing to ‘specialties’ achieved 86% approval, and 
leaving ‘extra-articular’ unchanged attained 69.4% of votes 
in a second ballot.
D. The goals of treating the patient with axial SpA or PsA 
are to optimise long-term health-related quality of life 
and social participation through control of signs and 
symptoms, prevention of structural damage, normalisation 
or preservation of function, avoidance of toxicities and 
minimisation of comorbidities. Compared with the previous 
version, the qualification ‘primary’, in the sense of ‘main’, 
for the goal was felt to be confusing, since several goals (and 
not just one) were mentioned thereafter. Therefore, it was 
suggested to simply delete ‘primary’ and replace goal by its 
plural form. This found an 86% approval. In a second ballot, 
the previous term ‘maximise’ was replaced by ‘optimise’ 
(72%). Discussions on specifying MRI regarding structural 
damage assessment and mentioning acute phase reactants in 
the context of this principle were not taken further here and 
postponed to deliberations on the specific recommendations. 
Of note and in reference to discussions mentioned above, 
comorbidities are specifically included here.
E. Abrogation of inflammation is important to achieve these 
goals. Compared with previous principle D, which stated 
that ‘abrogation of inflammation is presumably important’, 
‘presumably’ was now deleted, since sufficient evidence had 
accumulated over the last 5 years that inflammation is pivotal 
for progression of damage.39 50–52 Therefore, even though PsA 
is not a homogeneous disease and up to one-third of patients 
may have non-progressive arthritis where this paradigm may 
not apply,53 in the majority of patients, interference with 
inflammation is needed to achieve good outcomes. It was also 
suggested to exchange the word ‘abrogation’ by ‘elimination’ 
because this might be better understood; however, reference 
to the patient version of RA recommendations revealed that 
this term can be easily transposed for lay people.54 There was 
94.4% agreement with the above version in the first ballot.
Recommendations
The task force next evaluated potential changes to the recom-
mendations. All options were acceptable, namely: to be left 
as they had originally been constructed, amended, deleted or 
expanded in number and/or changed in sequence. Adherence to 
the evidence available was the pivotal driver during this process. 
The previous recommendations and the proposals for amend-
ment by the SC were presented and discussed. This process 
resulted in a total of 11 bullet points.
1. The treatment target should be clinical remission/inactive 
disease of musculoskeletal (arthritis, dactylitis, enthesitis, 
axial disease) and extra-articular manifestations. This bullet 
point previously read: ‘A major treatment target should 
be clinical remission/inactive disease of musculoskeletal 
involvement (arthritis, dactylitis, enthesitis, axial disease), 
taking extra-articular manifestations into consideration’. 
Thus, from the perspective of the content, the updated 
recommendation remained similar, but it was shortened and 
a few items deleted. For example, it was not deemed neces-
sary to call the target a ‘major’ one, since remission should 
be the aim in essentially all patients, while the term ‘should’ 
inherently suggests that this may not always be achievable 
(see item 4). Also, the phrase ‘taking extra-articular mani-
festations into consideration’ already suggested that their 
reversal should be accounted for. Importantly, however, 
no clinical trial used remission or inactive disease as a 
target for a strategic trial. The only strategic trial currently 
published focused on MDA, which likely corresponds to a 
low disease activity state as it allows for residual activity in 
some items.49 On the other hand, there is sufficient indirect 
evidence to suggest that in axial SpA and PsA, progression 
of damage is most strongly inhibited in states of remission/
inactive disease; low disease activity including MDA also 
conveys good structural outcomes50 52 55 and physical func-
tion is maximised in remission.52 This recommendation was 
voted for by 75% of the participants in the first ballot.
2. The treatment target should be individualised based on 
the current clinical manifestations of the disease; the 
treatment modality should be considered when defining 
the time required to reach the target. The first part of 
this recommendation constituted the previous point 2; 
the term ‘according to’ was just replaced by ‘based on’. 
It was also suggested that the term ‘current’ was deleted 
or changed, since one treats ‘active’ disease; however, the 
group preferred to adhere to ‘current’, since rheumatolo-
gists would understand what was meant. In the course of 
the discussions, several task force members suggested to 
add a time aspect, since the T2T concept generally calls 
for timely adaptation of therapy if a treatment is insuffi-
ciently effective and that the target and the time to reach 
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the target are related concepts. On the other hand, the time 
point at which one can discern a good from a minor or no 
response differs depending on the drugs used (eg, shorter 
with non-steroidal anti-inflammatory drugs) than biologic 
(b) DMARDs or methotrexate). Thus, an interim proposal 
for this recommendation read: ‘The treatment target and 
the time to reach the target should be individualised based 
on the current clinical manifestations of the disease and the 
treatment modality’. The opinion was then expressed that 
the target and the time to reach the target, while related, 
constituted separate concepts and, therefore, should 
be separated. With respect to timelines, treatment with 
DMARDs should show significant improvement within 
3 months and attainment of the target within 6 months. 
These considerations resulted in the present version which 
attained a 94.4% approval.
3. Clinical remission/inactive disease is defined as the absence 
of clinical and laboratory evidence of significant disease 
activity. This recommendation, which defines item 1, 
ultimately remained almost unchanged compared with 
2012, but three discussion points were raised. First, it was 
suggested to exclude the need for laboratory evidence in 
the definition, because MDA, and also clinical DAPSA,25 
did not include C reactive protein (CRP) or erythrocyte 
sedimentation rate (ESR) in their formulae and were still 
associated with good outcomes. The opposite view related 
to the fact that APR levels were significantly associated 
with progression of damage both in PsA and axial SpA,38 56 
and therefore should not be excluded from assessment of 
disease activity. Moreover, APRs are the only objective 
measure of articular or spinal disease activity (especially 
in axial SpA) and reflect the same dimension as activity of 
arthritis or of spondylitis. It is noteworthy that this recom-
mendation refers to ‘clinical remission/inactive disease’, in 
other words, it does not call for remission/inactive disease 
by imaging techniques such as sonography or MRI. Never-
theless, both DAPSA remission and a Boolean remission 
definition focusing on musculoskeletal items, but not MDA 
or CPDAI, were associated with minimal sonographic 
activity in PsA.57 58 Finally, the question was raised whether 
having the concept of remission was necessary or rather the 
terms inactive disease or minimal disease activity would be 
sufficient. However, in the course of the discussion several 
participants mentioned that the concept of remission was 
essential for rheumatic diseases, since it implies a cure-like 
state with no further progression of damage; importantly 
in this context, damage is associated with active joint or 
spinal disease, potentially even progressing slightly in low 
disease activity.39 50 52 As a result of these deliberations, this 
recommendation was approved in the first ballot by 88.9% 
of the task force members.
4. Low/minimal disease activity may be an alternative treat-
ment target. Stringent remission, as defined in point 3, may 
be difficult to achieve in many patients in clinical practice, 
especially in those with long-standing disease or substan-
tial comorbidities. The discussion focused on the need to 
understand the potential failure to attain a state named 
remission, since this failure could be a consequence of the 
instruments used; in particular, including physical func-
tion in an index may preclude attaining remission in those 
patients in whom function is severely impaired due to signif-
icant damage. This has been seen in ankylosing spondylitis 
(AS), where ASAS partial remission includes function36 and 
is less frequently achieved than ASDAS inactive disease.59 
Of note, ASDAS terminology refers to low disease activity 
as moderate disease activity, since the disease activity states 
include ‘very high’ in addition to ‘high’; this should be 
considered when interpreting ASDAS data or using ASDAS 
in practice. It was then discussed that the Health Assess-
ment Questionnaire Disability Index (HAQ) was just one 
item of several in the MDA criteria set or other indices, 
such as the CPDAI or GRACE, and patients could fulfil the 
other elements. However, allowing only six items to be 
achievable in the MDA, for example, may still decrease the 
chances of reaching a satisfactory status. MDA was applied 
as target in TICOPA, an open-label but controlled clinical 
trial, which allowed the SLR to adjudicate a high level of 
evidence (2b) to the trial  and to this item with a grade of 
recommendation of B10 (table 3). All task force members 
acknowledged the importance of this first-in-disease 
randomised strategic trial. By corollary, since low disease 
activity is an alternative target to remission, higher disease 
activity states are unacceptable, unless these are due to 
explicit patient preferences or reduction of disease activity 
is precluded by comorbidities or risks. Thus, ultimately the 
agreement on the treatment target should be based on a 
shared decision making between clinicians and patients. 
This recommendation achieved a 97.2% approval.
5. Disease activity should be measured on the basis of clinical 
signs and symptoms, and acute phase reactants. Initially, the 
question was raised if imaging should also be included when 
speaking of disease activity assessments. However, this 
suggestion was refuted because there are no data justifying 
the use of imaging in follow-up as yet and it is not feasible 
to perform MRI every few weeks in axial SpA. In early RA, 
following patients using ultrasound to target sonographic 
remission was not superior to clinical follow-up and a waste 
of healthcare resources.60 61 In light of the deliberations on 
point 3, no further discussions on the use of APRs in clinical 
practice ensued. This item remained unchanged compared 
with the 2012 version and achieved a 88.9% majority vote.
6. Validated measures of musculoskeletal disease activity and 
assessment of cutaneous and/or other relevant extra-ar-
ticular manifestations should be used in clinical practice 
to define the target and to guide treatment decisions; the 
frequency of the measurements depends on the level of 
disease activity. This item is related to recommendation 10 
of the 2012 version. However, it was one of the recom-
mendations, which had been separately developed for axial 
SpA, peripheral SpA and PsA. Since all three recommen-
dations had many components in common, it was deemed 
appropriate to combine them into a single recommenda-
tion. Previously, this item partly referred to specific instru-
ments, such as Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI)62 plus APRs or ASDAS, with or without 
measures of function such as Bath Ankylosing Spondylitis 
Functional Index63’ for axial SpA, or ‘arthritis, dactylitis, 
enthesitis, axial disease’ and ‘cutaneous manifestations’ for 
PsA. It was felt that the aspect of specific scores should be 
separated from the more general parts and that extra-ar-
ticular manifestations should be considered in PsA and in 
peripheral and axial SpA, given the potential for wide-
ranging clinical manifestations, by which they are also 
classified.64 Thus, this general comment was expanded 
and somewhat reworded to include cutaneous and ‘other 
relevant extra-articular manifestations’, indicating that 
eye (uveitis) and bowel (IBD) manifestations should also 
be considered, in line with overarching principle C. The 
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2012 recommendation included the notion that the vali-
dated measures should also be ‘documented regularly’; 
this was now omitted, but it should be part of standard 
of care in the context of the T2T recommendations that 
results of measuring disease activity must be recorded in 
the patients’ charts. Also, in line with the previous version, 
it is recommended that patients with high disease activity 
should be rheumatologically evaluated at short intervals 
(every 1–3 months), while those who achieved the treat-
ment target could be followed less frequently, such as every 
6–12 months; hence, the dependence on disease activity. As 
ultimately worded, this recommendation obtained 84.4% 
of the votes.
7. In axial SpA, ASDAS is a preferred measure and in PsA 
DAP SA or MDA should be considered to define the target. 
This bullet point addresses the clinical assessment of axial 
SpA and PsA, which was a focus of intensive debates during 
the consensus meeting. The discussion addressed both SpA 
subentities separately for some time, although there was 
some intermix in the course of these deliberations.
Regarding axial SpA, the 2012 version had suggested the 
assessment of ASDAS and/or BASDAI plus CRP. However, 
it was mentioned that the discrimination of BASDAI 
plus CRP is not as good as that of ASDAS and a model 
with ASDAS versus one including BASDAI and CRP was 
more closely correlated with syndesmophyte formation.65 
Indeed, ASDAS is more associated with various biomarkers 
of inflammation than BASDAI66 and correlates better with 
MRI changes.67 When ASAS partial remission was brought 
into the discussion, it became clear that, as stated before, it 
comprises physical function which is primarily an outcome 
variable and partly dependent on spinal damage, making it 
less responsive and discriminative than ASDAS. However, 
colleagues from the USA felt that the requirement of a labo-
ratory measure (CRP) in the ASDAS could decrease feasi-
bility in the USA in daily clinical practice, since laboratory 
testing may not always be possible on or sometimes even 
close to the date of the visits. It was counter-argued that 
CRP from the previous visit could be used when the patient 
was in the office and ASDAS could be corrected once the 
new laboratory evaluation was available, or a CRP could 
already be collected before the office visit, but this may 
not be generally feasible. Moreover, recommendation 3 
states that remission should also be defined by laboratory 
markers, so a CRP value should be obtained to be able to 
comply with this recommendation.
After this discussion on assessment of axial SpA, scoring 
systems for disease activity of PsA became again a heavily 
debated topic. It was restated by some members that from 
a methodological viewpoint composite measures should 
table 3 The 2017 updated treat-to-target recommendations for spondyloarthritis
loe GoR Voting
loA (0–10)
Mean (sd)
Overarching principles
A. The treatment target must be based on a shared decision between patient and rheumatologist n.a. n.a. 69.4% 9.7 (0.7)
B. Treatment to target by measuring disease activity, and adjusting therapy accordingly, improves outcomes n.a. n.a. 83.3% 9.3 (1.2)
C. SpA and PsA are multifaceted systemic diseases; the management of musculoskeletal and extra-articular 
manifestations should be coordinated, as needed, between the rheumatologist and other specialists (such as 
dermatologist, gastroenterologist, ophthalmologist)
n.a. n.a. 86.1% 9.8 (0.5)
D. The goals of treating the patient with SpA or PsA are to optimise long-term health-related quality of life and 
social participation through control of signs and symptoms, prevention of structural damage, normalisation or 
preservation of function, avoidance of toxicities and minimisation of comorbidities
n.a. n.a. 86.1% 9.9 (0.3)
E. Abrogation of inflammation is important to achieve these goals n.a. n.a. 94.4% 9.2 (1.8)
Recommendations
1. The treatment target should be clinical remission/inactive disease of musculoskeletal (arthritis, dactylitis, 
enthesitis, axial disease) and extra-articular manifestations
5 D 75% 9.2 (1.8)
2. The treatment target should be individualised based on the current clinical manifestations of the disease; the 
treatment modality should be considered when defining the time required to reach the target
5 D 94.4% 9.6 (0.8)
3. Clinical remission/inactive disease is defined as the absence of clinical and laboratory evidence of significant 
disease activity
2c B 88.9% 9.6 (0.6)
4. Low/minimal disease activity may be an alternative treatment target 2b/5* B/D* 97.2% 9.6 (0.9)
5. Disease activity should be measured on the basis of clinical signs and symptoms, and acute phase reactants 2c B 88.9% 9.3 (0.9)
6. Validated measures of musculoskeletal disease activity and assessment of cutaneous and/or other relevant 
extra-articular manifestations, should be used in clinical practice to define the target and to guide treatment 
decisions; the frequency of the measurements depends on the level of disease activity
5 D 84.4% 9.4 (0.8)
7. In axial SpA, ASDAS is a preferred measure and in PsA DAPSA or MDA should be considered to define the 
target
2c B 51.6% 7.9 (2.5)
8. The choice of the target and of the disease activity measure should take comorbidities, patient factors and 
drug-related risks into account
5 D 91.4% 9.5 (1.7)
9. In addition to clinical and laboratory measures, imaging results may be considered in clinical management 5 D 93.9% 9.1 (1.3)
10. Once the target is achieved, it should ideally be maintained throughout the course of the disease 2c B 100% 9.8 (0.5)
11. The patient should be appropriately informed and involved in the discussions about the treatment target, and 
the risks and benefits of the strategy planned to reach this target
5 D 76.5% 9.9 (0.4)
*2b (A) for PsA, 5 (D) for axial SpA.
ASDAS, Ankylosing Spondylitis Disease Activity Score; DAPSA, Disease Activity index for PSoriatic Arthritis; LoA, level of agreement among the task force members (mean (SD); 
LoE, level of evidence and GoR, grade of recommendation, both according to the Oxford Centre of Evidence-Based Medicine (evidence as provided by clinical trials underlying 
the recommendation); MDA, Minimal Disease Activity; n.a., not applicable; PsA, psoriatic arthritis; SpA, spondyloarthritis.
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ideally be unidimensional.28 68 This view was opposed by 
others stating that a multidimensional measure such as 
CPDAI and PASDAS allowed the physician to see indi-
vidual jmgdomain responses while providing a compre-
hensive measure of inflammatory disease activity. The 
discussion continued with the question, why one needed 
to bring them together and then still look at them sepa-
rately rather than leaving them separate; to calculate the 
composite scores one must have the individual component 
scores. Those suggesting separate assessments mentioned 
that not all drugs have similar efficacy on all domains, 
based on the genetic and pathogenic heterogeneity of the 
disease69; consequently, a drug may convey a good result 
when using a multidimensional score due to an excellent 
effect on the skin, but lack efficacy on an individual aspect 
of the disease, such as the joints. They further asked if a 
drug should be approved for PsA on the basis of results 
of such a composite measure. The dermatologists among 
the task force members mentioned that fumarates, which 
are primarily used in Europe, have significant effects on the 
skin and only modest benefit on the articular disease.70 71 
Similarly, cyclosporine has only little effect on arthritis72 
and inhibition of interleukin-17 has similar efficacy as 
tumour necrosis factor-inhibition on joints but a more 
profound effects on the skin.73 Additional information on 
PsA scores comes from a post hoc analysis of the Psoriasis 
Randomised Etanercept STudy in subjects with psoriatic 
Arthritis (PRESTA)  trial in which a 100 mg weekly dose of 
etanercept was compared with 50 mg weekly. At 12 though 
not at 24 weeks the CPDAI but not the DAPSA distin-
guished treatment response between the two doses.74 In the 
original trial, however, no significant difference of artic-
ular, dactylitis and enthesitis scores was observed between 
the doses at any time point; only the Psoriasis Area and 
Severity Index (PASI) differentiated between the doses at 12 
but not 24 weeks.75 Etanercept is approved at 50 mg weekly 
for PsA and at 100 mg weekly (for the first 12 weeks) for 
psoriasis. Notably management recommendations by both 
GRAPPA and EULAR suggest different treatment algo-
rithms when patients present with a predominance of 
arthritis, enthesitis or skin involvement.2 3 Generally T2T 
recommendations are not dealing with recommendations 
on individual therapies but, as stated before, are of generic 
nature; the treatment-related considerations addressed here 
have been specifically mentioned during the meeting or in 
the course of manuscript development in relation to the 
validity of instruments used to assess PsA activity and are 
thus pertinent for the general aspects of the discussion and 
not to make any therapeutic inferences.
Importantly, it was generally agreed that all manifesta-
tions of PsA needed to be assessed and that for each of the 
domains validated measures existed, but there was disa-
greement whether to bring them together into one score 
or evaluate them separately. One task force member stated 
that recommendations are also important to educate rheu-
matologists to include assessment of the skin and other 
manifestations when dealing with patients with PsA; 
dermatologists should at least also enquire about joint 
manifestations. Recommendations should provide a goal 
for attaining better disease control and should not be based 
solely on feasibility considerations. Others asked if rheu-
matologists should then be forced to perform detailed skin 
and other assessments, given that their main focus is the 
arthritic component and that scores needed to be feasible 
in light of the time constraints in clinical practice that have 
been identified as factors limiting T2T. Some rheumatolo-
gists may prefer to cooperate with a dermatologist when 
making treatment decisions for patients with more severe 
skin disease rather than making their own decisions, in line 
with overarching principle C.
Feasibility was seen as an important aspect of the appli-
cability of a score23 and from this perspective separate 
assessment of individual domains (musculoskeletal and 
cutaneous), in line with items 1 and 6 of the recommenda-
tions, was regarded by some to be more feasible and inform-
ative than combining them in a global composite measure. 
Furthermore, the question whether evidence existed for 
the contribution of skin involvement, or other measures 
that are not joint-related, to progression of joint damage 
in patients with PsA is unresolved; however, quality of life 
is strongly influenced by both musculoskeletal and skin 
disease. Regarding skin involvement, the dermatologists 
mentioned that a PASI of 1 or a Bosy Surface Area (BSA) of 
3, as would be compatible with MDA or even fulfilment 
of very low disease activity (VLDA) criteria, that is, seven 
out of the seven components of the MDA, was less relevant 
than the contextual aspects: a BSA of 1, being equal to one 
palm of overall skin involvement, would be seen differently 
depending on the localisation of the skin affection (eg, face) 
and the patients’ illness perception. However, the BSA 
thresholds of 1 and 3 are in line with the new T2T recom-
mendations in psoriasis developed by the National Psoriasis 
Foundation.76 A proposal to revalidate the DAPSA with the 
addition of a skin component was contested in light of the 
methodological aspect of unidimensionality. Likewise, the 
suggestion to revalidate MDA by deleting skin involvement 
and HAQ and adding CRP was countered by those who felt 
that skin should be included for face validity considering a 
construct of overall disease activity and that MDA had been 
used in the TICOPA trial as originally constructed.
At some point, the discussion was stopped because all 
arguments had already been heard with no resolution of 
the methodological dissent. Given this difference of opin-
ions, it was suggested that further research needed to be 
performed in PsA. In the field of axial SpA, the situation 
was much clearer, even though the evidence was less direct. 
Therefore, the way was paved for voting just on axial SpA.
Thus, the initial ballot involved only the first part of the 
current recommendation. However, the first proposal 
stating that ASDAS was ‘the’ preferred measure attained 
only 59.4% of the votes, rather than the necessary 75%. 
The ensuing discussion focused around the fact that a 
recommendation to use the ASDAS did not imply that it 
was mandatory to use the ASDAS and it was proposed 
to replace ‘“the” preferred measure’ by ‘“a” preferred 
measure’.
At this point in time, a task force member voiced the disap-
pointment regarding the sole focus on instruments for axial 
SpA, in light of the significant advancements in the PsA 
field since the days of the last T2T consensus. It was prop-
ositioned to also include PsA-specific assessments in the 
recommendation. It was remarked that neither had a stra-
tegic trial been performed in axial SpA hitherto nor had the 
ASDAS been used in such strategy; therefore, it was felt that 
the overall levels of information for axial SpA and PsA were 
not so disparate as to justify focusing on axial SpA alone. 
It was further argued that the only strategic trial published 
in the wide field of SpA had been performed in PsA, using 
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MDA as an anchor for advancing therapy,49 and that, just as 
much as ASDAS, both the continuous DAPSA (focusing on 
joint involvement) and MDA (a binary measure of disease 
state covering important domains of PsA including joints, 
skin and entheses) had been shown to have construct validity 
and were easy to perform in clinical practice. MDA defines 
a state; DAPSA allows definition of all disease activity states 
as well as levels of response to treatment.77 It was further 
stated that several items of the research agenda developed 
in 2012 (validation of scores, definition of disease activity 
states, response criteria, remission definition, therapeutic 
strategic trial)1 had been fulfilled for PsA and that, there-
fore, indeed the focus should not only be on axial SpA.
After this plea, the second part of the current recom-
mendation was proposed, but attained only 53.1% of the 
votes. Subsequent proposals also failed to now achieve a 
two-thirds majority. In a final ballot, the wording as stated 
in the recommendation was accepted by a simple majority 
of 51.6% of the participants. Of note, >70% of the task 
force members assigned a level of agreement of 8 or higher 
in the anonymous vote after the meeting (see below).
8. The choice of the target and of the disease activity measure 
should take comorbidities, patient factors and drug-related 
risks into account. This recommendation is similar to item 6 
in 2012. An interim proposal read: ‘Comorbidities, patient 
factors and drug characteristics including risks should be 
considered when choosing the target and interpreting 
disease activity scores and the level of the target; drug 
characteristics including risks, should also be taken into 
account’. The discussion centred around the need to incor-
porate ‘drug characteristics including risks’, since drug-re-
lated risks would not influence the choice of the instrument 
but rather only of the target. The term patient factors refers 
to patient preferences or individual patient situations, such 
as a particular profession which may require a more or a 
less stringent treatment target. The question arose if patient 
input should also be addressed here, but it was argued 
that this aspect was already comprised in the overarching 
principles. Also, some felt that the recommendation was 
quite lengthy. Nevertheless, a ballot on the interim version 
took place, but attained only a 68.6% rather than a 75% 
majority. After further debates and reformulation attempts, 
the recommendation as now worded achieved a 91.4% 
majority.
9. In addition to clinical and laboratory measures, imaging 
results may be considered in clinical management. This is 
a new recommendation which relates to previous item 9 
from the common trunk and the various items 11 from 
the specific recommendations approved in 2012. The 
part on ‘functional impairment, extra-articular manifesta-
tions, comorbidities and treatment risks’ was deleted from 
previous bullet point 9, since it was addressed in other 
items. The portion on ‘clinical and laboratory measures’ 
was reworded and brought to the front of the recommen-
dation, since these measures should be the main focus of 
assessment. Of note, the term imaging results relates to all 
imaging modalities, conventional radiography, MRI and 
sonography, in line with what had been stated in points 
9 and 11 in 2012. While imaging is not recommended as 
a target, it may assist where there is doubt if a target has 
been reached (ie, if the target was not reached because of 
inflammation or other reasons). This recommendation, as 
a replacement of previous numbers 9 and 11, achieved a 
93.9% majority.
10. Once the target is achieved, it should ideally be maintained 
throughout the course of the disease. This recommen-
dation is almost identical to no. 7 from 2012 version. It 
was deemed a logical consequence of the items related to 
attainment of the target and there was almost no discus-
sion—100% of the participants voted for this wording.
11. The patient should be appropriately informed and involved 
in the discussions about the treatment target, and the risks 
and benefits of the strategy planned to reach this target. 
This recommendation is identical to no. 8 of the 2012 
version. Some slight rewordings did not appeal to the task 
force. Also, a discussion on the addition of the term ‘treat-
ment goals’ rather than ‘treatment target’ took place, but 
it was ultimately agreed that the term ‘target’ was used 
throughout the document and should not be weakened. 
The current wording was approved by 76.5% of the task 
force members.
After the task force meeting, the overarching principles and 
specific recommendations were placed into a logical sequence 
and then subjected to anonymised electronic voting regarding 
the levels of agreement. These results, together with the levels 
of evidence and strengths of recommendations are presented 
next to each item (table 3). The task force members’ LoA with 
the overarching principles ranged from 9.2 to 9.9 out of 0–10, 
reflecting a high level of agreement. Likewise, the LoA with 10 
of the individual recommendations ranged from 9.1 to 9.9. Only 
recommendation 7 reached a lower LoA, namely 7.9. It is note-
worthy that two participants did not agree at all (score of 0), 
nine gave scores of 5–7, but the majority (70.3%) still bestowed 
scores between 8 and 10 (13 scored 10) to this recommendation.
The updated recommendations are also captured in an algo-
rithm (figure 2).
Research agenda
While several points of the previous research agenda have been 
answered now, other items remained open and new research 
questions arose. These are listed in table 4.
dIscussIon
T2T has been widely used for several decades to improve 
outcomes of non-rheumatic diseases.78–80 More recently, T2T 
strategies have also entered the field of rheumatology and T2T 
recommendations for RA were published at the beginning of this 
decade.81 In the interim, T2T recommendations have also been 
developed for gout and systemic lupus erythematosus (SLE).82 83 
In 2012, an international task force had also developed T2T 
recommendations for treating SpA, including AS and PsA.1
While treatment recommendations should be based on available 
evidence, neither the T2T recommendations for gout or SLE nor 
the previous ones for SpA derived from clear evidence showing 
the superiority of such steered treatment approach. They arose 
from a strong belief that this would be the case, with support from 
indirect information. Moreover, the recommendations elicited 
awareness of an important unresolved question and a pertinent 
research agenda. This agenda was indeed published as part of the 
SpA recommendations and many research questions raised several 
years ago have now been answered.
For example, one research question related to the validation 
and definition of disease activity and response criteria. Subse-
quently, several composite measures were validated,12 disease 
activity states defined and response criteria developed.77 A 
further quest was the definition of remission, which was also 
attained for PsA (remission) and axial SpA (inactive disease).77 84 
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The research question regarding the importance of including 
all domains of PsA or axial SpA in the remission definition is 
still unresolved. There are conflicting data on the magnitude 
of influence of psoriasis on physical function as measured by 
the HAQ.85 86 Yet another research question related to differ-
ences between low disease activity and remission in terms of 
outcomes which was clearly the case.52 87 Likewise, the question 
regarding the relationship between disease activity and damage 
found a clear answer.38 50 52 Finally, the pursuit of designing and 
performing a therapeutic trial comparing steered therapy aiming 
at remission or low disease activity with non-steered treatment 
was also completed in PsA.49
Thus, a large part of the research agenda posed in 2012 was 
addressed over the last few years; therefore, it was deemed 
timely to re-evaluate the recommendations. The committee went 
through at times lengthy discussions, but ultimately formulated 5 
overarching principles and 11 recommendations, which received 
very high levels of agreement in a final anonymous ballot. Most 
importantly, while all recommendations developed in 2012 had 
a very low LoE and GoR (5 and D, respectively), 5 of the 11 
recommendations in 2017 are now based on B grades of recom-
mendation, a clear advancement in 5 years.
Another aspect deserves mention: the 2012 task force originally 
planned to develop three separate sets of recommendations, one 
each for axial SpA (AS), PsA and peripheral SpA (such as reactive 
and IBD arthritis) and finally arrived at nine common and two 
additional separate recommendations for each of the SpA subsets. 
Now the task force did not even discuss separate recommendations 
Figure 2 Algorithm based on the 2017 update of the treat-to-target recommendations for spondyloarthritis. axSpA, axial SpA; CRP, C-reactive 
protein; DAPSA, Disease Activity index for PSoriatic Arthritis; MDA, Minimal Disease Activity; PsA, psoriatic arthritis; SpA, spondyloarthritis.
table 4 Research agenda
Axial involvement in PsA  ► Do spinal and peripheral involvements respond similarly or differently?
Enthesitis, dactylitis  ► More data need to be attained on the response of dactylitis or enthesitis to different therapies when compared with arthritis and skin 
disease.
 ► How does dactylitis or enthesitis affect physical function, health-related quality of life, social participation or cardiovascular risk?
 ► To what extent does their inclusion in composite measures increase or decrease validity and sensitivity to change?
Skin involvement  ► More data need to be attained on the response of psoriasis to different therapies when compared with arthritis and other musculoskeletal 
symptoms.
 ► How does skin involvement affect physical function or cardiovascular risk?
 ► To what extent does its inclusion in composite measure increase or decrease validity and sensitivity to change?
 ► To what extent do skin changes affect quality of life, work participation and social inclusion beyond the respective effects of arthritis and 
other musculoskeletal manifestations?
Imaging  ► Is imaging useful for follow-up in axial SpA and PsA?
 ► Should imaging remission be a treatment target in axial SpA and PsA?
Functioning/disabillity  ► What is the impact of functioning/disability in composite measures developed for PsA?
Strategic trials  ► Strategic trials in axial SpA and at least one additional strategic trial in PsA.
Maintenance of response  ► How can response be maintained?
 ► Can the dose of the therapy employed be reduced or the interval of applications be expanded and outcome maintained?
Care by specialists  ► Is care of axial SpA, peripheral SpA or PsA by a specialist (such as a rheumatologist) advantageous for outcomes when compared with care 
by a non-specialist?
Patient  ► Is outcome different when patients are informed in a structured way when compared with more general means of information?
Harmonisation  ► Nomenclature should be harmonised—remission vs inactive disease; minimal disease activity vs low disease activity, etc.
Structural damage  ► Does achievement of the treatment target result into prevention or retardation of structural damage development in the spine/peripheral 
joints in SpA?
Biomarkers  ► We need better biomarkers of disease activity than CRP for both axial SpA and PsA.
AS, ankylosing spondylitis; CRP, C-reactive protein; PsA, psoriatic arthritis; SpA, spondyloarthritis.
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for axial SpA, peripheral SpA and PsA, since all respective items 10 
and 11 in 2012 were very similar, indeed.1 Thus, while 9 plus 2×3 
recommendations had been developed in 2012, this committee 
arrived at a total of 11 rather than 15 points. While trials in 
patients with peripheral SpA other than PsA were not found in the 
SLR, it is noteworthy that DAPSA had originally been derived and 
validated in reactive arthritis.25
The wording of the overarching principles, for which no 
evidence was sought as they relate to very general conduct and 
treatment approaches, was more focused and the sequence 
slightly amended compared with the 2012 recommendations. 
Shared decision-making between patients and rheumatolo-
gists, recognition of the multiple facets of SpA, adjustment of 
therapy according to disease activity and targeting optimisation 
of health-related quality of life by abrogating inflammation 
continue to be their major aspects. Thus, the overarching princi-
ples remained essentially similar.
With respect to the individual recommendations, items 
1–5 are very similar when compared with 2012. Targeting 
remission/inactive disease (item 1) and, as an alternative, low/
minimal disease activity (number 4) are the mainstays of treat-
ment to target. Remission was defined as the absence of clinical 
and laboratory evidence of significant disease activity (item 3). 
Likewise, the need to individualise therapy in line with disease 
manifestations (number 2) and disease activity assessment by 
measuring clinical signs and symptoms as well as acute phase 
reactants (item 5) was upheld. The use of validated measures 
of musculoskeletal disease activity, but also of extra-articular 
manifestations, previously presented as the 10th and 11th 
recommendations, is now addressed as point 6.
Item 7 is now more specific than previous item 10 in terms 
of the recommendation of specific instruments. For axial 
SpA, ASDAS is now more clearly highlighted as assessment 
tool. Some discussion arose around this instrument, since it 
comprises CRP which is often not immediately available in 
clinical practice, although it was clarified that a previous CRP 
measurement could be used until the new laboratory result 
became available. Moreover, recommendations no. 3 and 5 
state that the target should include clinical and laboratory 
measures, which implies that CRP should be obtained irrespec-
tive of whether it is included in the ASDAS or kept separately. 
The focus on ASDAS in this recommendation puts the previous 
inclusion of BASDAI plus CRP into the background, which 
also respects the high discriminative capacity and sensitivity to 
change of ASDAS.66
For PsA, DAPSA and MDA are now explicitly mentioned, 
although other instruments are not discounted, awaiting further 
evaluation. DAPSA includes CRP, but as it is unidimensional it 
focuses only on joint involvement, incorporating patient global 
and pain assessments, but does not include a measurement of 
skin abnormalities nor non-articular musculoskeletal involve-
ment; these manifestations need to be separately evaluated, 
as mentioned in items 1 and 6. MDA comprises peripheral 
arthritis, enthesitis and skin involvement, but since it does not 
include a laboratory variable (as addressed in items 3 and 5), 
this should be separately evaluated. It is the only target evalu-
ated in a T2T study to date.49 There is concern about the inclu-
sion of physical function in MDA as this may reflect damage 
as well as activity and thus be less appropriate for patients 
with longstanding disease and irreversible disability. Of note, 
MDA is a state and thus useful as a target. DAPSA allows one 
to all define states, includingremission or low disease activity. 
It constitutes a more PsA-specific joint-related measure than 
those applied in numerous pivotal clinical trials performed for 
the approval of new drugs and advancement of our treatment 
armamentarium, which used RA-derived assessments. Disease 
activity states have also been defined for the various multidi-
mensional indices, such as CPDAI, GRACE and PASDAS.24 88
The subsequent three recommendations, items 8–10, focus 
on the necessity to take comorbidities and risks of therapy 
into consideration, the possibility to consider using imaging 
tools in addition to clinical and laboratory assessments (not 
instead) and the importance of sustaining a good outcome, 
once achieved. The final point reiterates overarching principle 
A by addressing information on and discussion of the treat-
ment approaches with the patient. Thus, in their totality, these 
recommendations are ‘framed’ by the basic aspect of thorough 
physician-patient interactions in the context of planning for 
and making any therapeutic decisions.
With the exception of one item, the level of agreement with the 
recommendations was generally very high, on average exceeding 
a level of 9 on a scale between 0 and 10. Item 7, which addressed 
specific tools, attained a somewhat lower level of agreement 
based on the various controversies around this issue as detailed 
previously. Nevertheless, even this recommendation achieved a 
mean level of agreement of almost 8 (out of 10), corroborating 
the decision made by the task force. However, it should be 
acknowledged that the task force did not reach agreement about 
the use of unidimensional versus multidimensional instruments 
for assessing disease activity in PsA. In contrast, the unidimen-
sional approach to evaluate disease activity in axial SpA, which 
can also exhibit multiorgan involvement although less frequently 
than PsA, was not disputed.
Of particular importance, the current recommendations do 
not address any specific type of treatment but rather deal with 
a general approach to treating SpA; management recommen-
dations, in contrast, deal with specific drugs for particular 
situations and have been specifically developed by respective 
committees, focusing on differences in management depending 
on the predominance of activity in specific disease domains.2–4 
The current task force comprised a large number of experts 
which included several patients and a health professional. 
Among the rheumatologists, all had experience in the treat-
ment of axial and peripheral SpA and most even had clinical 
trial experience. The development of the recommendations 
adhered to the EULAR SOPs for developing recommenda-
tions11 and the recommendations are aimed at healthcare 
providers and patients as well as at clinical trialists, regulators 
and hospital or health insurance administrators. Also, a new 
research agenda has been developed.
In summary, an update of recommendations to treat SpA to 
target is presented based on new evidence accrued over the past 5 
years. These recommendations are summarised in a Table, but all 
textual explanations are part and parcel of the recommendations. 
They are also depicted in a simple algorithm presented in figure 2. 
Adhering to these recommendations may significantly improve 
outcomes in patients with axial and peripheral SpA and PsA.
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